| 2868- | HNK, | Honokiol: A review of its pharmacological potential and therapeutic insights |
| - | Review, | Var, | NA | - | Review, | Sepsis, | NA |
| 2867- | HNK, | Honokiol ameliorates oxidative stress-induced DNA damage and apoptosis of c2c12 myoblasts by ROS generation and mitochondrial pathway |
| - | in-vitro, | Nor, | C2C12 |
| 2866- | HNK, | Honokiol and its analogues as anticancer compounds: Current mechanistic insights and structure-activity relationship |
| - | Review, | Var, | NA |
| 2865- | HNK, | Liposomal Honokiol induces ROS-mediated apoptosis via regulation of ERK/p38-MAPK signaling and autophagic inhibition in human medulloblastoma |
| - | in-vitro, | MB, | DAOY | - | vitro+vivo, | NA, | NA |
| 2864- | HNK, | Honokiol: A Review of Its Anticancer Potential and Mechanisms |
| - | Review, | Var, | NA |
| 2863- | HNK, | Honokiol induces paraptosis-like cell death through mitochondrial ROS-dependent endoplasmic reticulum stress in hepatocellular carcinoma Hep3B cells |
| - | in-vitro, | Liver, | Hep3B |
| 2886- | HNK, | Liposomal honokiol inhibits non-small cell lung cancer progression and enhances PD-1 blockade via suppressing M2 macrophages polarization |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 | - | in-vivo, | NA, | NA |
| 2885- | HNK, | Honokiol: a novel natural agent for cancer prevention and therapy |
| 2902- | HNK, | Rad, | Honokiol Mitigates Ionizing Radiation-Induced Injury by Maintaining the Redox Balance of the TrxR/Trx System |
| - | in-vitro, | Nor, | BEAS-2B |
| 2901- | HNK, | doxoR, | Honokiol protects against doxorubicin cardiotoxicity via improving mitochondrial function in mouse hearts |
| - | in-vivo, | Nor, | NA |
| 2899- | HNK, | SIRT3 activator honokiol ameliorates surgery/anesthesia-induced cognitive decline in mice through anti-oxidative stress and anti-inflammatory in hippocampus |
| - | in-vivo, | Nor, | NA |
| 2887- | HNK, | Honokiol Restores Microglial Phagocytosis by Reversing Metabolic Reprogramming |
| - | in-vitro, | AD, | BV2 |
| 2888- | HNK, | Honokiol mediated inhibition of PI3K/mTOR pathway: A potential strategy to overcome immunoresistance in glioma, breast and prostate carcinoma without impacting T cell function |
| - | in-vitro, | Var, | PC3 | - | in-vitro, | BC, | BT549 |
| 2889- | HNK, | doxoR, | Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice |
| - | in-vivo, | Nor, | NA |
| 2890- | HNK, | SIRT3 activation promotes enteric neurons survival and differentiation |
| 2891- | HNK, | Honokiol, an Active Compound of Magnolia Plant, Inhibits Growth, and Progression of Cancers of Different Organs |
| - | Review, | Var, | NA |
| 2892- | HNK, | Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | H385 | - | in-vitro, | Nor, | BEAS-2B |
| 2893- | HNK, | doxoR, | Honokiol protects against doxorubicin cardiotoxicity via improving mitochondrial function in mouse hearts |
| - | in-vivo, | Nor, | NA |
| 2894- | HNK, | Pharmacological features, health benefits and clinical implications of honokiol |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 2895- | HNK, | Mitochondria-Targeted Honokiol Confers a Striking Inhibitory Effect on Lung Cancer via Inhibiting Complex I Activity |
| - | in-vitro, | Lung, | PC9 |
| 2896- | HNK, | Honokiol inhibits hypoxia-inducible factor-1 pathway |
| - | in-vivo, | Colon, | CT26 |
| 2897- | HNK, | Honokiol Inhibits Proliferation, Invasion and Induces Apoptosis Through Targeting Lyn Kinase in Human Lung Adenocarcinoma Cells |
| - | in-vitro, | Lung, | PC9 | - | in-vitro, | Lung, | A549 |
| 2898- | HNK, | Honokiol Suppression of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Cell Biological Activity and Its Mechanism |
| - | in-vitro, | GC, | AGS | - | in-vitro, | GC, | NCI-N87 | - | in-vitro, | BC, | MGC803 | - | in-vitro, | GC, | SGC-7901 |
| 2900- | HNK, | The Role and Therapeutic Perspectives of Sirtuin 3 in Cancer Metabolism Reprogramming, Metastasis, and Chemoresistance |
| - | Review, | Var, | NA |
| 7374- | HOO, | Exploring Ozonated Vegetable Oils as Antimicrobial and Functional Agents in Food Systems: A Systematic Narrative Review |
| - | Review, | Nor, | NA |
| 7373- | HOO, | Effects of topical ozonated olive oil on lipid profile, quality of life, wound healing and glycemic control in patients with diabetic foot ulcers: a randomized controlled trial |
| - | Trial, | Diabetic, | NA |
| 7372- | HOO, | Ozone-modified properties of pumpkin seed oil as anti-H. pylori, anticancer, anti-diabetic and anti-obesity agent |
| - | in-vitro, | Pca, | PC3 |
| 7371- | HOO, | Phytochemical characterization of peanut oil and its ozonized form to explore biological activities in vitro |
| 7472- | Hops, | Modulation of breast cancer cell survival by aromatase inhibiting hop (Humulus lupulus L.) flavonoids |
| - | in-vitro, | BC, | SkBr3 |
| 7471- | Hops, | Spent hops (Humulus Lupulus L.) extract as modulator of the inflammatory response in lipopolysaccharide stimulated RAW 264.7 macrophages |
| - | in-vitro, | Nor, | RAW264.7 |
| 7470- | Hops, | Hops (Humulus lupulus) inhibits oxidative estrogen metabolism and estrogen-induced malignant transformation in human mammary epithelial cells (MCF-10A) |
| - | NA, | Nor, | MCF10 |
| 7469- | Hops, | CHEMOPREVENTIVE PROPERTIES OF SPENT HOPS (HUMULUS LUPULUS L.) EXTRACT AGAINST ANGIOGENESIS, INVASION AND MIGRATION OF COLORECTAL CANCER CELLS |
| - | in-vitro, | CRC, | SW48 | - | in-vitro, | CRC, | HT29 |
| - | Review, | Var, | NA |
| 7651- | HPT, | Rad, | Hyperthermia inhibits homologous recombination repair and sensitizes cells to ionizing radiation in a time- and temperature-dependent manner |
| - | in-vitro, | Var, | NA |
| 7650- | HPT, | Hyperthermia and radiation therapy for locally advanced or recurrent breast cancer |
| - | Trial, | BC, | NA |
| - | in-vivo, | Laryn, | FaDu |
| 7577- | HPT, | Rad, | Randomized trial of hyperthermia and radiation for superficial tumors |
| - | Trial, | Var, | NA |
| 7571- | HPT, | Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition |
| - | vitro+vivo, | Var, | NA |
| 7597- | HPT, | Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group |
| - | Trial, | Var, | NA |
| 7622- | HPT, | A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers |
| - | Review, | Var, | NA |
| - | Trial, | Pca, | NA | - | Trial, | BC, | NA |
| 7620- | HPT, | Hyperthermia and radiotherapy: physiological basis for a synergistic effect |
| - | Review, | Var, | NA |
| 7598- | HPT, | Rad, | Chemo, | The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials |
| - | Review, | Var, | NA |
| 7599- | HPT, | Rad, | Recent development on hyperthermia: An effective cotreatment improving radiotherapy outcome |
| - | Review, | Var, | NA |
| 7618- | HPT, | ESHO 2-85. Hyperthermia as an adjuvant to radiation therapy in the treatment of advanced neck nodes: A randomized multicenter study by the European Society for Hyperthermic Oncology |
| 7619- | HPT, | The role of hyperthermia in the treatment of tumor |
| 7575- | HPT, | Rad, | Chemo, | immuno, | From Localized Mild Hyperthermia to Improved Tumor Oxygenation: Physiological Mechanisms Critically Involved in Oncologic Thermo-Radio-Immunotherapy |
| 7574- | HPT, | Oxy, | Improvement of tumor oxygenation by mild hyperthermia |
| 7573- | HPT, | Rad, | Heat-induced BRCA2 degradation in human tumours provides rationale for hyperthermia-PARP-inhibitor combination therapies |
| - | vitro+vivo, | NA, | NA |
| 7572- | HPT, | Rad, | The effect of thermal dose on hyperthermia-mediated inhibition of DNA repair through homologous recombination |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Laryn, | FaDu |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid